Journal of Hepatology
Volume 50, Issue 4 , Pages 674-683 , April 2009

Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy

  • Jurriën G.P. Reijnders

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, ’s Gravendijkwal 230, Room Ha 204, 3015 CE Rotterdam, The Netherlands
    • ,
  • Suzan D. Pas

      Affiliations

    • Department of Virology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Martin Schutten

      Affiliations

    • Department of Virology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Robert A. de Man

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, ’s Gravendijkwal 230, Room Ha 204, 3015 CE Rotterdam, The Netherlands
    • ,
  • Harry L.A. Janssen

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, ’s Gravendijkwal 230, Room Ha 204, 3015 CE Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 (0) 10 703 5942; fax: +31 (0) 10 436 5916.

Received 11 June 2008 ,Revised 8 October 2008 ,Accepted 22 October 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ H.L.A. Janssen received grants from and is consultant for: Bristol Myers Squibb, Gilead, Novartis, Roche and Schering-Plough. R.A. de Man received an unrestricted research grant from Biotest, clinical trial support from Bristol Myers Squibb and Gilead, and is a member of the Data safety monitoring board of Novartis. The other authors have nothing to declare.

PII: S0168-8278(08)00804-0

doi: 10.1016/j.jhep.2008.10.033

Journal of Hepatology
Volume 50, Issue 4 , Pages 674-683 , April 2009

Article Tools

* Image Usage & Resolution